Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | CTH | P32929 | 1/20 | 0.36 |
| ▸ | CBS | P35520 | 1/20 | 0.36 |
| ▸ | THPO | P40225 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5356441 | 0.87 | BLM (0.33) | TSHRCTHCBSTHPOSMN1; SMN2 | |
| SCHEMBL5346360 | 0.87 | BLM (0.33) | TSHRCTHCBSTHPOSMN1; SMN2 | |
| SCHEMBL18129218 | 0.82 | THRB (0.41) | TSHRCTHCBSTHPOSMN1; SMN2 | |
| SCHEMBL816275 | 0.82 | ALDH1A1 (0.42) | TSHRCTHCBSTHPOSMN1; SMN2 | |
| SCHEMBL19170055 | 0.79 | LMNA (0.33) | TSHR | |
| SCHEMBL24414202 | 0.78 | TSHR (0.37) | TSHR | |
| SCHEMBL14963629 | 0.76 | TSHR (0.41) | TSHRCTHCBSTHPOSMN1; SMN2 | |
| SCHEMBL14904387 | 0.75 | PKM (0.33) | TSHRCTHCBSTHPOSMN1; SMN2 | |
| SCHEMBL859268 | 0.74 | — | — | |
| SCHEMBL5246328 | 0.73 | CES2 (0.40) | TSHRCTHCBSTHPOSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7195752-B2 | Surfactant compounds and uses thereof | GLAXO GROUP LIMITED (GB) | 2007-03-27 | — | — | US | claimed |
| EP-1486203-A2 | Surfactant compounds and uses thereof | GLAXO GROUP LIMITED (GB) | 2004-12-15 | — | — | EP | claimed |
| US-20040234556-A1 | Surfactant compounds and uses thereof | GLAXO GROUP LIMITED (GB) | 2004-11-25 | — | — | US | claimed |
| EP-1411896-A2 | SURFACTANT COMPOUNDS AND USES THEREOF | GLAXO GROUP LIMITED (GB) | 2004-04-28 | — | — | EP | claimed |
| WO-2003013610-A2 | SURFACTANT COMPOUNDS AND USES THEREOF | GLAXO GROUP LIMITED (GB) | 2003-02-20 | — | — | WO | claimed |
| EP-1486203-B1 | Surfactant compounds and uses thereof | GLAXO GROUP LTD (GB) | 2007-09-19 | — | — | EP | disclosed |
| US-7195752-B2 | Surfactant compounds and uses thereof | GLAXO GROUP LIMITED (GB) | 2007-03-27 | — | — | US | disclosed |
| EP-1411896-B1 | SURFACTANT COMPOUNDS AND USES THEREOF | GLAXO GROUP LTD (GB) | 2006-03-22 | — | — | EP | disclosed |
| EP-1486203-A2 | Surfactant compounds and uses thereof | GLAXO GROUP LIMITED (GB) | 2004-12-15 | — | — | EP | disclosed |
| US-20040234556-A1 | Surfactant compounds and uses thereof | GLAXO GROUP LIMITED (GB) | 2004-11-25 | — | — | US | disclosed |
| EP-1411896-A2 | SURFACTANT COMPOUNDS AND USES THEREOF | GLAXO GROUP LIMITED (GB) | 2004-04-28 | — | — | EP | disclosed |
| WO-2003013610-A2 | SURFACTANT COMPOUNDS AND USES THEREOF | GLAXO GROUP LIMITED (GB) | 2003-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040234556-A1 | Surfactant compounds and uses thereof | PFN1, SGMS1, SPTLC1 | TSHR 3083/4885CTH 1922/4885CBS 2087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.